Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy

Autor: Joanna Roder, Maria Giovanna Dal Bello, Giulia Barletta, Krista Meyer, Heinrich Roder, Federica Biello, Francesco Grossi, Carlo Genova, Erika Rijavec, Julia Grigorieva
Rok vydání: 2018
Předmět:
Male
0301 basic medicine
Oncology
Cancer Research
Lung Neoplasms
Platinum Compounds
Cohort Studies
0302 clinical medicine
Non-small cell lung cancer
Carcinoma
Non-Small-Cell Lung
Biomarkers
Chemotherapy
First line therapy
Prognosis
VeriStrat
Adult
Aged
80 and over
Antineoplastic Combined Chemotherapy Protocols
Carcinoma
Non-Small-Cell Lung
Female
Humans
Middle Aged
Neoplasm Staging
Predictive Value of Tests
Prospective Studies
Spectrometry
Mass
Matrix-Assisted Laser Desorption-Ionization
Survival Analysis
Prospective cohort study
Aged
80 and over
Hazard ratio
030220 oncology & carcinogenesis
Erlotinib
Veristrat
medicine.drug
Pulmonary and Respiratory Medicine
medicine.medical_specialty
03 medical and health sciences
Internal medicine
medicine
Lung cancer
Survival analysis
business.industry
Cancer
Spectrometry
Mass
Matrix-Assisted Laser Desorption-Ionization
medicine.disease
Clinical trial
030104 developmental biology
business
Zdroj: Lung Cancer. 117:64-69
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2017.12.007
Popis: Objectives VeriStrat® is a blood-based test that utilizes matrix-assisted laser desorption/ionization time-of-flight (MALDI ToF) mass spectrometry to assign a binary classification of VeriStrat Good or VeriStrat Poor that is associated with treatment outcomes in cancer patients. A number of other studies have shown an association between VeriStrat status and clinical outcomes in second and subsequent lines of therapy. The prognostic properties of VeriStrat were demonstrated in the placebo arms of two randomized studies in non-small cell lung cancer (NSCLC): TOPICAL and BR.21; the predictive properties of the test were shown in a prospective randomized phase III study PROSE in the second line treatment of NSCLC with erlotinib versus chemotherapy. Motivated by these observations, we sought to extend the clinical utility of VeriStrat to standard first line chemotherapy and evaluated the performance of the test in a number of clinical studies of patients treated with platinum-based regimens. Materials and methods We examine the performance of VeriStrat in three independent clinical trials where the test classification was acquired for prospectively collected baseline samples from 481 patients treated with platinum-based chemotherapy in first line. Results Across these trials, 66–70% of patients were classified as VeriStrat Good; patients classified as VeriStrat Good had significantly longer progression-free survival and overall survival than VeriStrat Poor patients, with hazard ratios ranging from 0.36 to 0.72 and 0.26 to 0.51, respectively. These results demonstrated that VeriStrat is a strong prognostic test in NSCLC patients treated with platinum-based regimens in the first line. Conclusion VeriStrat provides valuable clinical information that may be used to support patient-physician conversations regarding prognosis and treatment options, and to identify a subset of patients who might benefit from other treatment strategies, possibly in the framework of clinical trials.
Databáze: OpenAIRE
Externí odkaz: